NASDAQ:PASG Passage Bio (PASG) Stock Price, News & Analysis $0.62 -0.01 (-1.60%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Passage Bio Stock (NASDAQ:PASG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Passage Bio alerts:Sign Up Key Stats Today's Range$0.59▼$0.6350-Day Range$0.57▼$0.8252-Week Range$0.54▼$1.79Volume127,266 shsAverage Volume267,318 shsMarket Capitalization$37.91 millionP/E RatioN/ADividend YieldN/APrice Target$8.33Consensus RatingBuy Company OverviewPassage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Read More… Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> Passage Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks63rd Percentile Overall ScorePASG MarketRank™: Passage Bio scored higher than 63% of companies evaluated by MarketBeat, and ranked 444th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPassage Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePassage Bio has only been the subject of 1 research reports in the past 90 days.Read more about Passage Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Passage Bio are expected to grow in the coming year, from ($0.94) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Passage Bio is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Passage Bio is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPassage Bio has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Passage Bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.28% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Passage Bio has recently decreased by 1.18%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPassage Bio does not currently pay a dividend.Dividend GrowthPassage Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.28% of the float of Passage Bio has been sold short.Short Interest Ratio / Days to CoverPassage Bio has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Passage Bio has recently decreased by 1.18%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.38 News SentimentPassage Bio has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Passage Bio this week, compared to 1 article on an average week.Search Interest10 people have searched for PASG on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Passage Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Passage Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $65,405.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Passage Bio is held by insiders.Percentage Held by Institutions53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Passage Bio's insider trading history. Receive PASG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PASG Stock News HeadlinesPassage Bio présente des avancées dans la thérapie génique pour la démenceOctober 25, 2024 | fr.investing.comPassage Bio delivered preclinical, interim data at ESGCTOctober 25, 2024 | markets.businessinsider.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 31, 2024 | Porter & Company (Ad)Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual ConferenceOctober 24, 2024 | globenewswire.comADMA Biologics (NASDAQ:ADMA) & Passage Bio (NASDAQ:PASG) Head to Head ComparisonOctober 24, 2024 | americanbankingnews.comLe titre de Passage Bio atteint un plus bas de 52 semaines à 0,55$ face aux défis du marchéOctober 17, 2024 | fr.investing.comLe cours de l'action Passage Bio atteint un plus bas de 52 semaines à 0,57 $ face aux défis du marchéOctober 7, 2024 | fr.investing.comPassage Bio (NASDAQ:PASG) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comSee More Headlines PASG Stock Analysis - Frequently Asked Questions How have PASG shares performed this year? Passage Bio's stock was trading at $1.01 at the beginning of 2024. Since then, PASG shares have decreased by 38.6% and is now trading at $0.6199. View the best growth stocks for 2024 here. How were Passage Bio's earnings last quarter? Passage Bio, Inc. (NASDAQ:PASG) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.05. When did Passage Bio IPO? Passage Bio (PASG) raised $126 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Chardan was co-manager. How do I buy shares of Passage Bio? Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Passage Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Passage Bio investors own include Enovix (ENVX), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Rambus (RMBS), Toast (TOST), Globant (GLOB) and Luminar Technologies (LAZR). Company Calendar Last Earnings8/08/2024Today10/31/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PASG CUSIPN/A CIK1787297 Webwww.passagebio.com Phone267-866-0311FaxN/AEmployees130Year FoundedN/APrice Target and Rating Average Stock Price Target$8.33 High Stock Price Target$13.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,279.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-102,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.74% Return on Assets-52.29% Debt Debt-to-Equity RatioN/A Current Ratio7.67 Quick Ratio7.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.03 per share Price / Book0.30Miscellaneous Outstanding Shares61,641,000Free Float59,111,000Market Cap$37.24 million OptionableOptionable Beta1.19 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:PASG) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.